# THOR (NCT03390504)

> A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03390504
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Urothelial Cancer
- Interventions: Erdafitinib; Vinflunine; Docetaxel; Pembrolizumab; Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)
- Enrollment: 629
- Primary outcome: Overall Survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 107
- Podcasts: 48
- YouTube: 36
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=thor-nct03390504

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03390504", "email": "<work email>"}; the inbox owner confirms by the emailed link.